Home/Filings/4/0001127602-15-012125
4//SEC Filing

ALLERGAN INC 4

Accession 0001127602-15-012125

CIK 0000850693operating

Filed

Mar 18, 8:00 PM ET

Accepted

Mar 19, 7:33 PM ET

Size

18.8 KB

Accession

0001127602-15-012125

Insider Transaction Report

Form 4
Period: 2015-03-17
Transactions
  • Disposition to Issuer

    Nonemployee Director Stock Option (Right to Buy)

    2015-03-1711,4000 total
    Exercise: $46.66Exp: 2019-04-30Common Stock (11,400 underlying)
  • Disposition to Issuer

    Nonemployee Director Stock Option (Right to Buy)

    2015-03-1711,4000 total
    Exercise: $60.60Exp: 2017-05-01Common Stock (11,400 underlying)
  • Disposition to Issuer

    Nonemployee Director Stock Option (Right to Buy)

    2015-03-174,3050 total
    Exercise: $166.32Exp: 2024-05-06Common Stock (4,305 underlying)
  • Disposition to Issuer

    Common Stock

    2015-03-1727,1670 total
  • Disposition to Issuer

    Nonemployee Director Stock Option (Right to Buy)

    2015-03-179,0000 total
    Exercise: $51.72From: 2007-05-02Exp: 2016-05-02Common Stock (9,000 underlying)
  • Disposition to Issuer

    Nonemployee Director Stock Option (Right to Buy)

    2015-03-1711,4000 total
    Exercise: $54.32Exp: 2018-05-06Common Stock (11,400 underlying)
  • Disposition to Issuer

    Nonemployee Director Stock Option (Right to Buy)

    2015-03-1711,4000 total
    Exercise: $61.98Exp: 2020-04-29Common Stock (11,400 underlying)
Footnotes (5)
  • [F1]Pursuant to that certain Agreement and Plan of Merger dated November 16, 2014, (the "Merger Agreement") by and among the Issuer, Actavis, Plc ("Actavis) and a wholly-owned subsidiary of Actavis, the Issuer became an indirect wholly-owned subsidiary of Actavis upon consummation of the merger (the "Effective Date"). Each share of common stock was disposed of in exchange for $129.22 cash plus 0.3683 of an Actavis ordinary share, having a market value of $307.51 per share on the Effective Date.
  • [F2]The number of shares reported on this line item includes shares acquired pursuant to dividend rights attached to restricted stock units that were previously granted and reported as Table 1, Non-Derivative Securities.
  • [F3]The option was previously reported as covering 4,500 shares at an exercise price of $103.43. The issuer effected a two-for-one stock split on June 22, 2007, which resulted in 9,000 shares held by the reporting person at an exercise price of $51.7150.
  • [F4]The option was previously reported as covering 5,700 shares at an exercise price of $121.20. The Issuer effected a two-for-one stock split on June 22, 2007, which resulted in 11,400 shares held by the reporting person at an exercise price of $60.60.
  • [F5]Each option vested in full on the Effective Date and was cancelled in exchange for a cash payment equal to the number of shares subject to the option immediately prior to the merger, multiplied by the difference between (i) 0.3683 times $294.1509 (which represents the 10-day volume weighted average price of Actavis stock starting on the 11th trading day prior to the closing) plus $129.22 and (ii) the exercise price of the option, subject to the applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.

Issuer

ALLERGAN INC

CIK 0000850693

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000850693

Filing Metadata

Form type
4
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 7:33 PM ET
Size
18.8 KB